Amgen has shelved its once-promising psoriasis drug. Motley Fool's Michael Douglass and Todd Campbell help investors understand the impact.

The Motley Fool’s Sean O’Reily and Vincent Shen discuss the latest buyout news concerning Time Warner Cable.

The Motley Fool’s Sean O’Reilly and Dylan Lewis discuss the latest moves being made by Google to conquer the world of mobile.

The Motley Fool's Tyler Crowe, Taylor Muckerman, and Sean O'Reilly discuss a slew of energy sector downgrades by Wall Steet investment banks and why long term investors should just ignore them.

Johnson & Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C someday. Motley Fool's Michael Douglass and Todd Campbell dig into the details of this deal to see if Gilead Sciences investors should worry.

The Motley Fool’s Sean O’Reilly and Vincent Shen discuss the energy drink market and how the world’s major beverage players are positioning themselves to cash in on this emerging trend.

Technology is revolutionizing the financials space as we know it, from lending to investment advising, and more! 

On today’s edition of Industry Focus, we’ll hear how Facebook is taking iOS to the next level by making news available instantly, without leaving the comfort of your social media page. 

This week we saw two big buys with Noble Energy buying Rosetta Resources and Williams Companies buying out its subsidiary. Is this a signal that the merger and acquisition wave might actually happen? Taylor Muckerman and Tyler Crowe break down these deals and give some insight as to why the merger wave is taking so long and how these deals could shape the future landscape. 

Motley Fool's Michael Douglass and Todd Campbell dig into MannKind Corp.'s first quarter earnings to see if MannKind is a bargain, or a bust.